Contact Information: INVESTOR CONTACT: Debbie Bailey 631-444-8090 fax: 631-444-8848 MEDIA CONTACT: Janice Meraglia 631-444-6293 fax: 631-444-8848 FCMN Contact: Web site: http://www.adnas.com
Applied DNA Sciences Expands Executive Sales Team
Veteran Consultants Help to Drive Strategic Business Development Programs
| Source: Applied DNA Sciences
STONY BROOK, NY--(Marketwire - October 13, 2009) - Applied DNA Sciences, Inc. (OTCBB : APDN ), a
provider of DNA-based security solutions, announced that it has expanded
its sales force to include a number of veteran industry and government
consultants who will be responsible for driving sales and strategic
business initiatives throughout the U.S. and abroad. The new additions
include Joseph L. Magno, an expert in government relations, Warren M.
Pearlson, a veteran in pharmaceuticals, and others with expertise in
cash-in-transit, wine, textiles and B2B technology commercialization.
Mr. Magno brings extensive government experience and is working with APDN
to initiate strategies to effectively penetrate State and Federal
Government organizations. He successfully founded and led a number of
technologically-driven companies, his last being acquired and sold to
General Electric in 1996. Earlier in his career, Mr. Magno held positions
in sales and management in a number of large multi-national technology
companies. While serving in government, he advised both the New York State
Governor and Legislative Leadership on economic development, research and
education. Mr. Magno has served on a number of boards including NYSTAR,
University at Albany Bioscience Development Center, NYS Software Network,
NYS Institute for Entrepreneurship and currently serves on the Watervliet
Arsenal Partnership Board and the Albany Science and Technology Law Center
Board of Advisors.
"I am delighted to spearhead a number of initiatives to help protect
products within government supply and logistic chains and ultimately ensure
public safety. It's reassuring to know that DNA technology is available to
provide the necessary forensic checks and balances not sufficiently
addressed by other security measures," commented Mr. Magno.
Mr. Pearlson is a 25-year veteran in the pharmaceutical industry including
positions of increasing responsibility at Astra Pharmaceuticals, Warner
Lambert/Parke-Davis and most recently with Pfizer. His extensive industry
network of contacts and strategic management skills will establish the
client base most positively impacted by DNA technology.
"Companies have the ability and the obligation to put systems in place to
protect the public. Not only do counterfeit drugs defraud consumers, they
can cause great harm and even fatalities. DNA provides a forensic level of
confidence which is why it is so appealing to providers and consumers,"
stated Mr. Pearlson.
Over the last year, APDN has evolved an integrated, global matrix of sales
consultants and regional representatives compensated largely by sales
commissions. In addition to four newly appointed sales consultants, the
company recently began collaborating with a British Wine Master to help us
sell our authentication technologies in Bordeaux and throughout Europe.
"We have demonstrated our ability to execute and provide first-category
services across multiple sectors," said Dr. James Hayward, CEO of APDN.
"With the expansion of our sales force, we expect our sales cycle to
shorten and our penetration within sectors to increase."
About APDN
APDN sells patented DNA security solutions to protect products, brands and
intellectual property from counterfeiting and diversion. SigNature DNA is a
botanical mark used to authenticate products in a unique manner that
essentially cannot be copied. APDN also provides BioMaterial GenoTyping™
by detecting genomic DNA in natural materials to authenticate finished
products. Both technologies protect brands and products in a wide range of
industries and provide a forensic chain of evidence that can be used to
prosecute perpetrators. To learn more, go to www.adnas.com where APDN
routinely posts all press releases.
The statements made by APDN may be forward-looking in nature and are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements describe APDN's future
plans, projections, strategies and expectations, and are based on
assumptions and involve a number of risks and uncertainties, many of which
are beyond the control of APDN. Actual results could differ materially from
those projected due to our short operating history, limited financial
resources, limited market acceptance, market competition and various other
factors detailed from time to time in APDN's SEC reports and filings,
including our Annual Report on Form 10-K, filed on December 16, 2008 and
our subsequent quarterly reports on Form 10-Q. APDN undertakes no
obligation to update publicly any forward-looking statements to reflect new
information, events or circumstances after the date hereof to reflect the
occurrence of unanticipated events.